Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

10x Genomics (TXG) Inventory (2018 - 2026)

10x Genomics' Inventory history spans 8 years, with the latest figure at $56.3 million for Q4 2025.

  • On a quarterly basis, Inventory fell 32.21% to $56.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $56.3 million, a 32.21% decrease, with the full-year FY2025 number at $56.3 million, down 32.21% from a year prior.
  • Inventory hit $56.3 million in Q4 2025 for 10x Genomics, down from $62.0 million in the prior quarter.
  • Over the last five years, Inventory for TXG hit a ceiling of $94.0 million in Q3 2024 and a floor of $38.5 million in Q1 2021.
  • Historically, Inventory has averaged $71.0 million across 5 years, with a median of $74.2 million in 2023.
  • Biggest five-year swings in Inventory: skyrocketed 103.6% in 2021 and later plummeted 34.12% in 2025.
  • Tracing TXG's Inventory over 5 years: stood at $60.0 million in 2021, then skyrocketed by 36.13% to $81.6 million in 2022, then decreased by 9.71% to $73.7 million in 2023, then increased by 12.75% to $83.1 million in 2024, then plummeted by 32.21% to $56.3 million in 2025.
  • Business Quant data shows Inventory for TXG at $56.3 million in Q4 2025, $62.0 million in Q3 2025, and $69.0 million in Q2 2025.